Thelansis

 Thalassemia is an inherited blood disorder in which the production of functional hemoglobin is reduced (the protein in red blood cells that carries oxygen). This causes a shortage of red blood cells and low oxygen levels in the bloodstream, leading to various health problems. Mutations in the HBB gene lead to reduced levels of beta-globin and cause beta-thalassemia. Loss (deletion) of some or all of the HBA1 and/or HBA2 genes results in a shortage of alpha-globin, leading to alpha thalassemia.   Thelansis’s “Thalassemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thalassemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China)...

 Thalassemia is an inherited blood disorder in which the production of functional haemoglobin is reduced (the protein in red blood cells that carries oxygen). This causes a shortage of red blood cells and low oxygen levels in the bloodstream, leading to various health problems. Mutations in the HBB gene lead to reduced levels of beta-globin and cause beta-thalassemia. Loss (deletion) of some or all of the HBA1 and/or HBA2 genes results in a shortage of alpha-globin, leading to alpha thalassemia. Thelansis’s “Thalassemia Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Thalassemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KO...

Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin (the protein in red blood cells that carries oxygen). This causes a shortage of red blood cells and low levels of oxygen in the bloodstream, leading to a variety of health problems. Etiology- Mutations in the HBB gene lead to reduced levels of beta-globin and cause beta-thalassemia. Loss (deletion) of some or all of the HBA1 and/or HBA2 genes results in a shortage of alpha-globin, leading to alpha thalassemia. The competitive landscape of Thalassemia includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Thalassemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and ...